Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience

Abstract

There is international interest for consensus advice for prescribers working in the field of drug resistant epilepsy intending to trial potential therapies that are nonregistered or off‐label. Cannabinoids are one such therapy. In 2017, the New South Wales State Government (Australia) set up a cannabinoid prescribing guidance service for a wide variety of indications, based on known pharmacology together with the relevant new literature as it became available. Increasing interest in cannabis medicines use outside this State over the following 5 years together with a paucity of registration‐standard clinical trials, lack of information around dosing issues, drug interactions and biological plausibility meant there remained a large unmet need for such advice. To address the unmet need in epilepsy, and until medicines were registered or regulator quality data were available, it was agreed to bring together a working group comprising paediatric and adult epilepsy specialists, clinical pharmacists., clinical pharmacologists and cannabis researchers from across Australia to develop interim consensus advice for prescribers. Although interim, this consensus advice addresses much of the current practice gap by providing an informed overview of the different cannabis medicines currently available for use in the treatment of epilepsy in paediatric and adult settings, with information on dose, drug interactions, toxicity, type of seizure and frequency of symptom relief. As such it supplements the limited evidence currently available from clinical trials with experience from front‐line practice. It is expected that this consensus advice will be updated as new evidence emerges and will provide guidance for a subsequent Guideline.

Exploring the Significance of Pharmaceutical Care in Mental Health: A Spotlight on Cannabis

“…In this context, the role of pharmacists is fundamental in caring for patients seeking treatment with Cannabis for anxiety and depression symptoms. They provide guidance on the different types of Cannabis and their therapeutic effects, helping to choose the most suitable product [ 65 ]. In addition, pharmacists are responsible for calculating the correct dosages and monitoring patients to ensure treatment effectiveness and minimize side effects [ 51 ].…”

The Impact of P-Glycoprotein on Opioid Analgesics: What’s the Real Meaning in Pain Management and Palliative Care?

“…Many antiepileptic drugs (AEDs) are P-gp substrates, and their repeated administration leads to P-gp upregulation, thus resulting in drug resistance [41]. Recent clinical trials suggest the use of cannabinoids in refractory epilepsy, although the possible mechanism of action is still unclear [42]. In cultured vascular endothelial cells, cannabidiol has been shown to inhibit the efflux of the P-gp dependent rhodamine-123, similarly to the P-gp inhibitor tariquidar [43].…”

Complementary and alternative therapies in the palliative setting

“…Genetic polymorphism and the inhibition or induction of these transporters by one drug may result in changes in plasma drug concentrations of another drug. Clinical effects are commonly seen in the combination of cannabidiol and epilepsy therapies 20 . UDP‐glucuronosyltransferase (UGT) enzymes also represent an important pathway of metabolism.…”

“…Clinical effects are commonly seen in the combination of cannabidiol and epilepsy therapies. 20 UDP‐glucuronosyltransferase (UGT) enzymes also represent an important pathway of metabolism. The UGT family of enzymes catalyse glucuronic acid conjugation and play an important role in the metabolism and detoxification of many small molecule drugs, CAMs and endogenous compounds.…”